Highly complementary transaction strengthens BioAgilytix’s ability to support all phases of biologics development; adds to growing cell and gene therapy expertise; increases laboratory capacity; expands team of seasoned bioanalytical scientists; broadens geographic reach.
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, BioAgilytix, regarding the acquisition of Cambridge Biomedical.
BioAgilytix, a leading provider of large molecule bioanalytical testing services, today announced that it has acquired Cambridge Biomedical, a contract research organisation based in the Cambridge area of Massachusetts, which also specialises in large molecule bioanalysis. The transaction expands BioAgilytix’s global footprint into the heart of the world’s major biotech center, and adds further capacity by joining Cambridge Biomedical’s CLIA-certified, CAP-accredited, and GLP-compliant facility with its GxP laboratories in Durham, North Carolina and Hamburg, Germany. It also grows BioAgilytix’s premier team to more than 400 employees worldwide, bringing on board Cambridge Biomedical’s seasoned bioanalytical scientists to complement and further enhance BioAgilytix’s world-class expertise in biomarkers, immunogenicity, cell-based assays, and pharmacokinetics to support all phases of biologics development. Cambridge Biomedical has particularly extensive capabilities in kit production as well as a premier molecular suite equipped with the latest generation of PCR platforms, both of which will be immediately available to BioAgilytix’s customers.
“We’re proud to have Cambridge Biomedical join BioAgilytix in our collective mission to serve customers’ evolving and expanding bioanalytical needs” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “Our companies have many synergies, both exclusively focused in large molecules and today supporting development of some of the most innovative and complex biologics, including cell and gene therapeutics. We also share the same commitment to quality and service, which has allowed both companies to build a strong scientific track record and impressive customer base. Together we will be able to offer the same premier scientific solutions and quality results, but on a larger scale. Our customers will now have access to additional scientific resources and platforms in the Cambridge area of Massachusetts, which is a hotbed of biotech innovation, and Cambridge Biomedical’s customers will be able to leverage BioAgilytix’s premier labs in the Research Triangle area of North Carolina and in Hamburg, Germany to seamlessly support large and global studies.”
“As we were considering the best way to enable Cambridge Biomedical to continue on its strong growth trajectory, it became clear that we wanted a partner – one as committed to upholding our high scientific standards and ‘people first’ values” said Barbara Osband, Founder and Chief Executive Officer of Cambridge Biomedical. “Having personally spent more than 18 years building our business and creating a culture that recognises being in the health care industry mandates a special level of competence, caring, and integrity, I was thrilled to merge with BioAgilytix whose value systems mirror our own. I couldn’t be more confident placing Cambridge Biomedical in the capable hands of BioAgilytix’s leadership team.”“We have found in BioAgilytix a company that cares as deeply about scientific excellence as we do, and that shares our steadfast commitment to both our customers and employees,” said Linda Robbie, Ph.D., Senior Vice President of Science and Laboratory Operations at Cambridge Biomedical. “Throughout its 22-year history, Cambridge Biomedical has maintained a stellar reputation for high scientific and service standards, and we’ve experienced impressive growth in the last few years. We wanted a partner to help take our team to the next level, continuing to cultivate Cambridge Biomedical’s success by building on the core values that have brought us to where we are today. I couldn’t be happier to have our team join BioAgilytix, and I’m excited to see where we will go from here together. I know our customers on both sides will see many benefits from the uniting of our companies.”
Cambridge Biomedical was represented by Fairmount Partners throughout this transaction.